The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine ...

BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The Nobel Prize-winning scientific innovation underlying the COVID-19 vaccine proved to be a notable financial boon for the ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

Big moves are shaking up BioNTech (NASDAQ:BNTX) this week, and investors are taking notice. The German biotech heavyweight ...

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...

Acasunlimab is under clinical development by BioNTech and currently in Phase III for Non-Small Cell Lung Cancer.